GnRH Agonist and Antagonists in an Oocyte Donation Program
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary purpose of this study is to evaluate the effect of the two different protocols (long protocol vs antagonist protocol) on oocyte / embryo quality.
| Condition | Intervention | Phase |
|---|---|---|
|
Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality |
Drug: Cetrorelix and Leuprolide |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Crossover Assignment Masking: Open Label |
The cycles with antagonists of the GnRHa present a series of advantages with respect the GnRHa in an oocyte donation program: treatment cycles are simpler and shorter, a lower amount of dose of gonadotrophins is needed for stimulation, and most important, a decreased rate of ovarian hyperstimulation syndrome is observed. Nevertheless, several clinical trials relate their use to a greater rate of abortion and worse oocyte/ embryo quality. In order to discriminate the endometrial factor from the quality of oocyte cohort, the best strategy is the oocyte donation model. In the present study, for the first time, the effect of different protocols (long versus antagonist protocol) will be studied in the same donor, acting as its own control, undergoing COH. We will compare the COH´s parameters and IVF outcome obtained in the same donor submitted to, firstly, GnRH antagonist protocol (Cetrorelix- n= 45) versus another consecutive cycle with long protocol (Ac. Leuprolide- n= 45).
Eligibility| Ages Eligible for Study: | 18 Years to 34 Years |
| Genders Eligible for Study: | Female |
Inclusion Criteria:
- oocyte donors with age range: 18 - 34; BMI: 18 - 29 kg/m2;
Exclusion Criteria:
- PCO
Contacts and Locations| Spain | |
| Instituto Valenciano de Infertilidad Spain | |
| Valencia, Spain, 46015 | |
| Principal Investigator: | Marco Melo, MDPhD | Instituto Valenciano de Infertilidad |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00505817 History of Changes |
| Other Study ID Numbers: | VLC-MM-0706-307-19 |
| Study First Received: | July 23, 2007 |
| Last Updated: | January 9, 2009 |
| Health Authority: | Spain: Ministry of Health |
Additional relevant MeSH terms:
|
Cetrorelix Leuprolide Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Fertility Agents, Female Fertility Agents Reproductive Control Agents |
ClinicalTrials.gov processed this record on May 19, 2013